Crucell has signed an agreement to acquire Stockholm-based SBL Vaccin AB (SBL) from 3i and SEB for $50.6 million in cash. The acquisition is expected to close on November 23, 2006. SBL is an independent Swedish biotechnology company employing 120 people. SBL’s main product is Dukoral, an oral vaccine for protection against cholera and is registered in more than 50 countries excluding the U.S. Dukoral is also registered in the same countries (excluding the EU and Australia) to protect...